🟢 Humacyte is trading 9.51% up today after FDA discussions support November 2026 dialysis-access filing

Humacyte is trading at $0.73, up +9.51% after confirming FDA discussions support a supplemental BLA filing in November 2026 for ATEV dialysis access.

• Humacyte is extending the August 24, 2026 rally.
• The filing would seek a second approved indication after the December 2024 vascular-trauma approval, creating a company-specific catalyst.
• Broader biotech strength is also supportive, with XBI up 2.06%, though the FDA update remains the primary driver.